ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interleukin 1 Receptor Antagonist Protein

Also written as “Anakinra”, “Anakinra (Kineret®)” and “anakinra”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Familial Mediterranean Fever · COVID-19 · Still's Disease, Adult-Onset, led by 3 companies.

Drug pageInterleukin 1 Receptor Antagonist Protein: every studyAll 168 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 20, 200514 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen70 open or runningphase 4since May 20, 2005May 17, 2002none ahead
Swedish Orphan Biovitrumits history only61 open or runningphase 4since Oct 8, 2024Dec 13, 2016none ahead
Hamad Medicalits history only10 open or runningphase 3since Nov 24, 2020Nov 24, 2020none ahead

Also a collaborator on its studies: Tigermed Consulting and CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2002First studies: 3 phase 2 studiesFirst studyNCT00037648, NCT00037700, NCT00038298
  2. May 16, 2005Phase 2 study in OsteoarthritisNCT00110916 · 165 enrolled
  3. May 20, 2005Phase 4 study in Arthritis, RheumatoidNCT00111410
  4. Jun 30, 2005Phase 4 study in Arthritis, RheumatoidNCT00121043
  5. Jun 30, 2005Phase 3 study in Arthritis, RheumatoidNCT00117091

TargetBeta

IL1A →read by rule
“A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist ”NCIt, by rule

Other programs on IL1A

ProgramCompanyFurthest phaseStudies
lutikizumabAbbViephase 312
ABBV-1451AbbViephase 11

Studies

All 7 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00121043Arthritis, Rheumatoid4Completed
NCT00117091Arthritis, Rheumatoid3Completed
NCT00111410Arthritis, Rheumatoid4Completed
NCT00110916Osteoarthritis2CompletedFeb 2005165
NCT00038298Arthritis, Rheumatoid2CompletedMay 200453
NCT00037700Arthritis, Rheumatoid2Completed
NCT00037648Arthritis, Juvenile2CompletedNov 200386

How it is read

Names in the registry

  • “Anakinra”, 5 entries
  • “Anakinra (Kineret®)”, 2 entries
  • “anakinra”, 2 entries
  • “AMG 719”, 2 entries
  • “Anakinra 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.